Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

A struggling economy and a bear market haven’t been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Over the past year, the company’s shares are up by 17%. And Wall Street continues to be enamored with the drugmaker, which has a consensus buy rating, according to Yahoo! Finan